Andreas Halvorsen’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Andreas Halvorsen’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,026,656	Closed	-$56.9M	–	101
2022 Q2	$56.9M	Hold	2,026,656	–	–	0.26%	65
2022 Q1	$93.5M	Sell	2,026,656 -91,628	-4%	-$4.94M	0.38%	64
2021 Q4	$178M	Hold	2,118,284	–	–	0.51%	55
2021 Q3	$141M	Sell	2,118,284 -281,000	-12%	-$16.2M	0.39%	63
2021 Q2	$128M	Hold	2,399,284	–	–	0.39%	59
2021 Q1	$104M	Sell	2,399,284 -612,000	-20%	-$26.3M	0.31%	66
2020 Q4	$156M	Sell	3,011,284 -1,432,000	-32%	-$64.6M	0.43%	58
2020 Q3	$145M	Hold	4,443,284	–	–	0.52%	50
2020 Q2	$213M	Buy	+4,443,284	New	+$170M	0.92%	36

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Andreas Halvorsen's ZNTL Position: Q3 2022 in Review

Andreas Halvorsen sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2022, closing a stake of 2,026,656 shares — an estimated $56.9M sold.

Andreas Halvorsen first reported a position in ZNTL in Q2 2020 and held it in 9 quarters. The position peaked at $213M in Q2 2020. 120 funds tracked by Wall St. Rank hold ZNTL as of Q3 2022.

Andreas Halvorsen reported no remaining Zentalis Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Andreas Halvorsen sold 2,026,656 Zentalis Pharmaceuticals shares in Q3 2022, an estimated $56.9M.
Andreas Halvorsen first reported a position in Zentalis Pharmaceuticals in Q2 2020 and held it in 9 quarters.
Andreas Halvorsen's Zentalis Pharmaceuticals position peaked at $213M in Q2 2020.
120 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2022.

Based on Viking Global Investors's 13F filing for Q3 2022, filed 14 Nov 2022.